Researchers have discovered a protein that may predict disease severity for scleroderma-associated interstitial lung disease, the leading cause of death for patients with the rare autoimmune condition. Higher circulating levels of the CTRP9 were associated with more severe lung disease, while low levels were associated with preserved function.
Scleroderma has taken both of Lovette Twyman Russell’s lungs and the tips of three of her fingers, but not one ounce of her joy in life. For the 58-year-old former triathlete, getting the right treatment for this rare autoimmune disease – which causes abnormal growth of connective tissue and can permanently damage the joints, skin, cartilage and internal organs – has made all the difference.
People with the rare autoimmune disease scleroderma, who likely experience more serious isolation during a global pandemic, saw their anxiety and depression improve after receiving online mental health intervention through an international study. Researchers say the support program could be extended to many vulnerable patient populations moving forward.
A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
The March issue of The American Journal of Gastroenterology features new clinical research involving sex and gender, including effects of GI and liver conditions on pregnancy, gender disparities in diet and nutrition, Barrett’s esophagus incidence in women with scleroderma, factors influencing whether women pursue advanced endoscopy careers, endoscopy-related musculoskeletal injuries, sex hormone association with increased prevalence of certain types of cancer, and more.
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
Nationally recognized rheumatology expert Francesco Boin, MD, has been appointed director of the division of Rheumatology and director of the new Scleroderma Program at Cedars-Sinai. Boin is an accomplished and widely published investigator of autoimmune diseases, with a reputation for clinical excellence and a multidisciplinary approach to patient care.
Cedars-Sinai today announced a $20 million gift from Dr. and Mrs. Min H. Kao and the Kao Family Foundation to create the Kao Autoimmunity Institute to advance research and treatment of rheumatologic diseases. The gift also will establish the Scleroderma Program within the institute to provide interdisciplinary and integrated care for scleroderma patients and to support research, outreach, training and education to help those with the disease.